arrow
A

Andoni Echaniz-Laguna

Université Paris-Saclay
H指数:52
被引数:7,905

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rituximab With or Without Chemotherapy for Anti-MAG Neuropathy: A Retrospective Multicenter Real-World Study

利妥昔单抗联合或不联合化疗治疗抗-MAG神经病的回顾性多中心真实世界研究

2026-10-010
PRE
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy

Gillmore, J.D.; Gane, E.; Taubel, J.; Pilebro, B.; Echaniz-Laguna, A.; Kao, J.; Litchy, W.; Shahda, S.; Haagensen, A.; Walsh, L.; et al. Nexiguran ziclumeran基因编辑在遗传性ATTR伴多发性神经病变中的应用。N. Engl. J. Med. 2025, 393, 1375–1386. [Google Scholar] [CrossRef]

2025-09-013
PRE
Diagnostic Impasse and Wandering in Patients With Rare Neuromuscular Diseases: Insights Into Patient Characteristics From the French National Network for Rare Neuromuscular Diseases (FILNEMUS) and the French National Rare Disease Database (BNDMR)

罕见神经肌肉疾病患者的诊断困境与诊断延迟:来自法国罕见神经肌肉疾病国家网络(FILNEMUS)和法国国家罕见病数据库(BNDMR)的患者特征洞察

2025-09-010
OAAI
Nationwide Phenotypic and Genotypic Characterisation of 103 Patients With SH3TC2 Gene-Related Demyelinating Peripheral Neuropathy

全国范围内103例SH3TC2基因相关脱髓鞘周围神经病的表型和基因型特征分析

2025-07-310
OA
Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study
2023-10-192
PRE
Phenotype Presentation and Molecular Diagnostic Yield in Non-5q Spinal Muscular Atrophy
2023-08-016
OAAI
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis

tafamidis和肝移植作为遗传性转甲状腺素蛋白淀粉样变性一线治疗的比较

2023-02-164
OA
Convergence of patient-and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy
2022-03-023
OAAI
Galaxy Is a Suitable Bioinformatics Platform for the Molecular Diagnosis of Human Genetic Disorders Using High-Throughput Sequencing Data Analysis: Five Years of Experience in a Clinical Laboratory
2021-12-0611
OA
Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae
2021-10-0123
OAAI